Lundbeck drops Parkinson’s drug acquired ... - Cure Parkinson's

Cure Parkinson's

26,181 members27,513 posts

Lundbeck drops Parkinson’s drug acquired in €905m deal

Farooqji profile image
0 Replies

The Danish drugmaker said it had decided to terminate development of the first-in-class, oral glutamate mGluR4 positive allosteric modulator – which was Pexton’s only clinical-stage programme when it was bought in 2018 – after the drug missed all its objective in the phase 2 study..

pmlive.com/pharma_news/lund...

Written by
Farooqji profile image
Farooqji
To view profiles and participate in discussions please or .

Not what you're looking for?

You may also like...

Lundbeck bags a PhII Parkinson’s drug with $1.1B Prexton buyout deal

As per deal, Lundbeck is handing over $123 million and committing to about a billion dollars more...

Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2020

145 trials are registered and ongoing clinical trials for therapeutics targeting PD, of which 51...

Constipation in Parkinson’s disease

Parkinson,s disease for 14 years Constipation for 12 years Improvement now with Emma 1-2...

Mucuna pruriens in Parkinson’s

Mucuna pruriens in Parkinson’s disease: a double blind clinical and pharmacological study R...

In whom the pill drops.

The more I look at this site, the more I see alternative / complimentary / etc. therapies. Am I...